Millennium Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $163M | Sell |
1,275,800
-711,100
| -36% | -$88.8M | 0.07% | 268 |
|
|
2025
Q4 | $242M | Sell |
1,986,900
-1,327,800
| -40% | -$152M | 0.1% | 151 |
|
|
2025
Q3 | $332M | Sell |
3,314,700
-50,100
| -1% | -$4.51M | 0.14% | 90 |
|
|
2025
Q2 | $279M | Buy |
3,364,800
+44,700
| +1% | +$3.57M | 0.13% | 105 |
|
|
2025
Q1 | $269M | Sell |
3,320,100
-1,277,700
| -28% | -$114M | 0.14% | 96 |
|
|
2024
Q4 | $414M | Sell |
4,597,800
-215,900
| -4% | -$20.9M | 0.2% | 60 |
|
|
2024
Q3 | $476M | Buy |
4,813,700
+442,500
| +10% | +$43.5M | 0.23% | 46 |
|
|
2024
Q2 | $405M | Sell |
4,371,200
-66,600
| -2% | -$5.97M | 0.19% | 71 |
|
|
2024
Q1 | $421M | Buy |
4,437,800
+255,100
| +6% | +$23.7M | 0.18% | 65 |
|
|
2023
Q4 | $373M | Buy |
4,182,700
+228,200
| +6% | +$16.9M | 0.16% | 73 |
|
|
2023
Q3 | $289M | Buy |
3,954,500
+1,736,300
| +78% | +$139M | 0.15% | 87 |
|
|
2023
Q2 | $185M | Buy |
2,218,200
+21,000
| +1% | +$1.76M | 0.09% | 144 |
|
|
2023
Q1 | $167M | Sell |
2,197,200
-38,800
| -2% | -$3.22M | 0.1% | 156 |
|
|
2022
Q4 | $186M | Sell |
2,236,000
-1,214,400
| -35% | -$98.3M | 0.1% | 157 |
|
|
2022
Q3 | $274M | Sell |
3,450,400
-117,300
| -3% | -$9.89M | 0.16% | 56 |
|
|
2022
Q2 | $265M | Sell |
3,567,700
-672,700
| -16% | -$50.5M | 0.16% | 61 |
|
|
2022
Q1 | $381M | Sell |
4,240,400
-127,200
| -3% | -$11.7M | 0.2% | 45 |
|
|
2021
Q4 | $489M | Buy |
4,367,600
+2,248,800
| +106% | +$271M | 0.25% | 46 |
|
|
2021
Q3 | $266M | Buy |
2,118,800
+663,400
| +46% | +$85.4M | 0.16% | 77 |
|
|
2021
Q2 | $197M | Buy |
1,455,400
+862,200
| +145% | +$113M | 0.12% | 102 |
|
|
2021
Q1 | $80.5M | Buy |
593,200
+290,000
| +96% | +$43.4M | 0.06% | 308 |
|
|
2020
Q4 | $42.7M | Buy |
303,200
+4,600
| +2% | +$589K | 0.03% | 543 |
|
|
2020
Q3 | $33.3K | Buy |
298,600
+41,700
| +16% | +$4.67M | 0.04% | 506 |
|
|
2020
Q2 | $28.8M | Sell |
256,900
-241,800
| -48% | -$23.8M | 0.04% | 536 |
|
|
2020
Q1 | $38.6M | Sell |
498,700
-90,400
| -15% | -$8M | 0.09% | 222 |
|
|
2019
Q4 | $56M | Sell |
589,100
-40,200
| -6% | -$3.48M | 0.07% | 318 |
|
|
2019
Q3 | $48M | Buy |
629,300
+134,000
| +27% | +$11.1M | 0.08% | 319 |
|
|
2019
Q2 | $43.4M | Buy |
495,300
+125,700
| +34% | +$10.7M | 0.07% | 397 |
|
|
2019
Q1 | $33.5M | Buy |
+369,600
| New | +$31.4M | 0.05% | 518 |
|
|
2018
Q3 | – | Sell |
-237,600
| Closed | -$22.6M | – | 4321 |
|
|
2018
Q2 | $22.6M | Buy |
+237,600
| New | +$21.8M | 0.03% | 782 |
|
|
2018
Q1 | – | Sell |
-75,000
| Closed | -$6.37M | – | 4139 |
|
|
2017
Q4 | $6.37M | Sell |
75,000
-25,000
| -25% | -$2.09M | 0.01% | 1619 |
|
|
2017
Q3 | $8.66M | Sell |
100,000
-275,000
| -73% | -$22M | 0.01% | 1331 |
|
|
2017
Q2 | $28.9M | Buy |
375,000
+175,000
| +88% | +$12.4M | 0.05% | 520 |
|
|
2017
Q1 | $13.9M | Buy |
+200,000
| New | +$13.4M | 0.03% | 847 |
|
|
2015
Q4 | – | Sell |
-250,000
| Closed | -$15.6M | – | 3811 |
|
|
2015
Q3 | $15.6M | Buy |
+250,000
| New | +$19.7M | 0.03% | 689 |
|
|
2015
Q2 | – | Sell |
-75,000
| Closed | -$5.64M | – | 3918 |
|
|
2015
Q1 | $5.64M | Sell |
75,000
-75,000
| -50% | -$5.24M | 0.01% | 1350 |
|
|
2014
Q4 | $9.32M | Buy |
+150,000
| New | +$8.55M | 0.02% | 1034 |
|
|
2014
Q2 | – | Sell |
-232,200
| Closed | -$11M | – | 3952 |
|
|
2014
Q1 | $11M | Buy |
+232,200
| New | +$11.9M | 0.03% | 754 |
|
|
2013
Q4 | – | Sell |
-369,000
| Closed | -$15.9M | – | 3839 |
|
|
2013
Q3 | $15.9M | Buy |
+369,000
| New | +$14.9M | 0.05% | 469 |
|
Other funds holding XBI
Millennium Management's XBI Position: Q1 2026 in Review
Millennium Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 273% in Q1 2026, buying an estimated $3.19M and bringing the position to 34,918 shares worth $4.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3081.
Millennium Management first reported a position in XBI in Q1 2014 and has held it in 33 quarters since. The position peaked at $89.5M in Q4 2023. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Millennium Management held 34,918 shares of State Street SPDR S&P Biotech ETF worth $4.46M as of Q1 2026.
- Millennium Management bought 25,548 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $3.19M.
- State Street SPDR S&P Biotech ETF made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3081 holding.
- Millennium Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2014 and has held it in 33 quarters since.
- Millennium Management's State Street SPDR S&P Biotech ETF position peaked at $89.5M in Q4 2023.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.